DISEASE CONTROL & ELIMINATION SEED FUNDING

Lead Research Organisation: MRC Unit, The Gambia

Abstract

The Disease Control & Elimination theme aims at providing scientific knowledge to control/eliminate disease of public health importance in sub-Saharan Africa such as malaria, hepatitis B, trachoma, and bacterial diseases. Different approaches are used, from descriptive studies to clinical or intervention trials. Research activities produce baseline knowledge that can be used to formulate new scientific proposals to be submitted for external funding.

Technical Summary

The Disease Control & Elimination theme aims to conduct cutting-edge, multidisciplinary research to develop approaches to curb the burden of diseases of public health importance. The inclusion of the word “elimination” in the theme definition encompasses the research portfolio that includes trachoma, a disease that has almost been eliminated in The Gambia, and malaria, for which pre-elimination level should be achieved by 2018. The research on hepatitis B within the theme provides a link between the control of communicable and non-communicable diseases, i.e. hepatitis B infection and hepatocellular carcinoma. The Disease Control & Elimination theme will exploit the availability of excellent laboratory facilities and the scope to carry out population studies to elucidate complex and heterogeneous host-pathogen/parasite-vector interactions. Understanding such interactions in areas under intensified disease control is critical for the development of scientifically-based control/elimination plans for the whole African continent. In-depth analysis of the human behavioural factors including migration that affect disease risk is an essential component of the theme’s methodological approach. Joint research projects with Institutions located in other West African countries allows a wider view of specific public health problems and provides the opportunity to compare the impact of new interventions in settings with different disease endemicities.

Publications

10 25 50
publication icon
Achan J (2018) Malaria medicines to address drug resistance and support malaria elimination efforts. in Expert review of clinical pharmacology

publication icon
Adetifa IM (2016) A tuberculosis nationwide prevalence survey in Gambia, 2012. in Bulletin of the World Health Organization

 
Description Mass drug administration of ivermectin and dihydroartemisinin-piperaquine as an additional intervention for malaria elimination (MASSIV). 
Organisation Durham University
Country United Kingdom 
Sector Academic/University 
PI Contribution This is a project funded by the Joint Global Health Trial Scheme for which funding was secured by us. It is a community-based, cluster-randomized trial carried out in the Upper River Region of The Gambia. Thirty two villages (clusters) at least 3-4km apart and with 200-600 inhabitants have been randomized to either the intervention or the control arm. MDA with IVM and dihydroartemisinin-piperaquine (DP) has been implemented in 16 intervention villages and any other human settlement in the buffer zone around intervention villages (2km). MDA consisted of 3-monthly rounds per year during the malaria transmission season for two years. Malaria prevalence at the peak of each transmission season and the mosquito population age structure has been compared between intervention and control arms.
Collaborator Contribution ITM Antwerp and Rovira i Virgili University provided expertise in medical anthropology. Radboud University provided expertise in parasitology, more specifically on maalria gametocyte biology and also on health economics; Durham University provided expertise in entomology; the National Malaria Control Program was involved in the formulation of the proposal and the implementation of field activities.
Impact Collaboration is multidisciplinary, see above. One publication. Others are in preparation.
Start Year 2017
 
Description Mass drug administration of ivermectin and dihydroartemisinin-piperaquine as an additional intervention for malaria elimination (MASSIV). 
Organisation Government of The Gambia
Department Ministry of Health Gambia
Country Gambia 
Sector Public 
PI Contribution This is a project funded by the Joint Global Health Trial Scheme for which funding was secured by us. It is a community-based, cluster-randomized trial carried out in the Upper River Region of The Gambia. Thirty two villages (clusters) at least 3-4km apart and with 200-600 inhabitants have been randomized to either the intervention or the control arm. MDA with IVM and dihydroartemisinin-piperaquine (DP) has been implemented in 16 intervention villages and any other human settlement in the buffer zone around intervention villages (2km). MDA consisted of 3-monthly rounds per year during the malaria transmission season for two years. Malaria prevalence at the peak of each transmission season and the mosquito population age structure has been compared between intervention and control arms.
Collaborator Contribution ITM Antwerp and Rovira i Virgili University provided expertise in medical anthropology. Radboud University provided expertise in parasitology, more specifically on maalria gametocyte biology and also on health economics; Durham University provided expertise in entomology; the National Malaria Control Program was involved in the formulation of the proposal and the implementation of field activities.
Impact Collaboration is multidisciplinary, see above. One publication. Others are in preparation.
Start Year 2017
 
Description Mass drug administration of ivermectin and dihydroartemisinin-piperaquine as an additional intervention for malaria elimination (MASSIV). 
Organisation Institute of Tropical Medicine Antwerp
Country Belgium 
Sector Academic/University 
PI Contribution This is a project funded by the Joint Global Health Trial Scheme for which funding was secured by us. It is a community-based, cluster-randomized trial carried out in the Upper River Region of The Gambia. Thirty two villages (clusters) at least 3-4km apart and with 200-600 inhabitants have been randomized to either the intervention or the control arm. MDA with IVM and dihydroartemisinin-piperaquine (DP) has been implemented in 16 intervention villages and any other human settlement in the buffer zone around intervention villages (2km). MDA consisted of 3-monthly rounds per year during the malaria transmission season for two years. Malaria prevalence at the peak of each transmission season and the mosquito population age structure has been compared between intervention and control arms.
Collaborator Contribution ITM Antwerp and Rovira i Virgili University provided expertise in medical anthropology. Radboud University provided expertise in parasitology, more specifically on maalria gametocyte biology and also on health economics; Durham University provided expertise in entomology; the National Malaria Control Program was involved in the formulation of the proposal and the implementation of field activities.
Impact Collaboration is multidisciplinary, see above. One publication. Others are in preparation.
Start Year 2017
 
Description Mass drug administration of ivermectin and dihydroartemisinin-piperaquine as an additional intervention for malaria elimination (MASSIV). 
Organisation Radboud University Nijmegen Medical Center
Country Netherlands 
Sector Academic/University 
PI Contribution This is a project funded by the Joint Global Health Trial Scheme for which funding was secured by us. It is a community-based, cluster-randomized trial carried out in the Upper River Region of The Gambia. Thirty two villages (clusters) at least 3-4km apart and with 200-600 inhabitants have been randomized to either the intervention or the control arm. MDA with IVM and dihydroartemisinin-piperaquine (DP) has been implemented in 16 intervention villages and any other human settlement in the buffer zone around intervention villages (2km). MDA consisted of 3-monthly rounds per year during the malaria transmission season for two years. Malaria prevalence at the peak of each transmission season and the mosquito population age structure has been compared between intervention and control arms.
Collaborator Contribution ITM Antwerp and Rovira i Virgili University provided expertise in medical anthropology. Radboud University provided expertise in parasitology, more specifically on maalria gametocyte biology and also on health economics; Durham University provided expertise in entomology; the National Malaria Control Program was involved in the formulation of the proposal and the implementation of field activities.
Impact Collaboration is multidisciplinary, see above. One publication. Others are in preparation.
Start Year 2017
 
Description Mass drug administration of ivermectin and dihydroartemisinin-piperaquine as an additional intervention for malaria elimination (MASSIV). 
Organisation Rovira i Virgili University
Country Spain 
Sector Academic/University 
PI Contribution This is a project funded by the Joint Global Health Trial Scheme for which funding was secured by us. It is a community-based, cluster-randomized trial carried out in the Upper River Region of The Gambia. Thirty two villages (clusters) at least 3-4km apart and with 200-600 inhabitants have been randomized to either the intervention or the control arm. MDA with IVM and dihydroartemisinin-piperaquine (DP) has been implemented in 16 intervention villages and any other human settlement in the buffer zone around intervention villages (2km). MDA consisted of 3-monthly rounds per year during the malaria transmission season for two years. Malaria prevalence at the peak of each transmission season and the mosquito population age structure has been compared between intervention and control arms.
Collaborator Contribution ITM Antwerp and Rovira i Virgili University provided expertise in medical anthropology. Radboud University provided expertise in parasitology, more specifically on maalria gametocyte biology and also on health economics; Durham University provided expertise in entomology; the National Malaria Control Program was involved in the formulation of the proposal and the implementation of field activities.
Impact Collaboration is multidisciplinary, see above. One publication. Others are in preparation.
Start Year 2017